Literature DB >> 10328712

Parkinsonism after taking ecstasy.

S Mintzer, S Hickenbottom, S Gilman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10328712     DOI： 10.1056/nejm199905063401817

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450.

Authors:  H R Sumnall; L Jerome; R Doblin; M C Mithoefer
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

2.  The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance.

Authors:  Maartje M L De Win; Gerry Jager; Hylke K E Vervaeke; Thelma Schilt; Liesbeth Reneman; Jan Booij; Frank C Verhulst; Gerard J Den Heeten; Nick F Ramsey; Dirk J Korf; Wim Van den Brink
Journal:  Int J Methods Psychiatr Res       Date:  2005       Impact factor: 4.035

Review 3.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 4.  Substance of abuse and movement disorders: complex interactions and comorbidities.

Authors:  Andres Deik; Rachel Saunders-Pullman; Marta San Luciano
Journal:  Curr Drug Abuse Rev       Date:  2012-09

Review 5.  The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.

Authors:  H Kalant
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

Review 6.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

7.  Persistent nigrostriatal dopaminergic abnormalities in ex-users of MDMA ('Ecstasy'): an 18F-dopa PET study.

Authors:  Yen F Tai; Rosa Hoshi; Catherine M Brignell; Lisa Cohen; David J Brooks; H Valerie Curran; Paola Piccini
Journal:  Neuropsychopharmacology       Date:  2010-12-15       Impact factor: 7.853

Review 8.  Psychostimulants and movement disorders.

Authors:  Andres Asser; Pille Taba
Journal:  Front Neurol       Date:  2015-04-20       Impact factor: 4.003
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.